Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated
with prognosis of patients: a clinical high-grade endometrial carcinoma
prognostic model
Abstract
Objectives: To evaluate the predictive significance of
neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in the
prognosis of high-grade endometrial carcinoma and to establish a novel
predictive model. Design: A retrospective multicenter study. Setting:
Fifteen hospitals of the Chinese Endometrial Carcinoma Consortium.
Population: This study included 910 high-grade epithelial endometrial
carcinoma patients from the multicenter who underwent initial surgical
treatment between January 1, 2005, and December 31, 2019. Methods: Data
was retrospectively obtained from the medical records and follow-up
information of patients. Cox proportional hazard regression models were
developed to predict the risk of recurrence and death at 3, 5, and 10
years, and the models were validated and calibrated. The area under the
curve was used to measure the predictive performance of the model. Main
outcomes measures: Disease-free survival and overall survival. Result:
Platelet-lymphocyte ratio and neutrophil-lymphocyte ratio were risk
factors for recurrence, and neutrophil-lymphocyte ratio was a risk
factor for death. We established models for predicting death and
recurrence. In the validation cohort, the area under receiver operating
characteristic curve of disease-free survival model at 3,5 and 10 years
was 0.72, 0.77, 0.77, and of overall survival model was 0.72, 0.81, and
0.84. Kaplan–Meier survival analysis showed a significant difference
between low-risk and high-risk groups. Conclusions:
Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are risk
factors affecting the prognosis of high-grade endometrial carcinoma
patients. This novel prediction model for high-grade endometrial
carcinoma can provide accurate postoperative risk classification and
prognosis prediction for patients. Keywords: Endometrial carcinoma,
prognostic model, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio